Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

329 ARTÍCULOS , VIENDO DEL 166 AL 180

[Major challenges]

Longerich B.

Krankenpfl Soins Infirm. 2013;106(9):51.

[Bed-manager or health-care circuit manager]

Cieslik M, Legendre M, de Decker L, Berrut G.

Geriatr Psychol Neuropsychiatr Vieil. 2013 Dec;11(4):337-8. doi: 10.1684/pnv.2013.0429.

[Practice example: neurodegenerative disorders: randomised controlled multicentre trial of home-based occupational therapy for patients with dementia]

Voigt-Radloff S, Hüll M.

Z Evid Fortbild Qual Gesundhwes. 2013;107(3):222-8. doi: 10.1016/j.zefq.2013.04.001. Epub 2013 May 14.

Rivastigmine patch ameliorates depression in mild AD: preliminary evidence from a 6-month open-label observational study

Spalletta G, Gianni W, Giubilei F, Casini AR, Sancesario G, Caltagirone C, Cravello L.

Alzheimer Dis Assoc Disord. 2013 Jul-Sep;27(3):289-91. doi: 10.1097/WAD.0b013e318260ab0a.

Enhancing the salience of fluency improves recognition memory performance in mild Alzheimer's disease

Bastin C, Willems S, Genon S, Salmon E.

J Alzheimers Dis. 2013;33(4):1033-9. doi: 10.3233/JAD-2012-121678.

Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline

Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, Sadowsky CH, Nair AK, Siderowf A, Lu M, Arora AK, Agbulos A, Flitter ML, Krautkramer MJ, Sarsour K, Skovronsky DM, Mintun MA; 45-A17 Study Group.

Alzheimer Dis Assoc Disord. 2013 Jan-Mar;27(1):4-15. doi: 10.1097/WAD.0b013e318279d02a.

Nucleic acid aptamers as novel class of therapeutics to mitigate Alzheimer's disease pathology

Tannenberg RK, Shamaileh HA, Lauridsen LH, Kanwar JR, Dodd PR, Veedu RN.

Curr Alzheimer Res. 2013 May 1;10(4):442-8. doi: 10.2174/1567205011310040009.

Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data

Niva C, Parkinson J, Olsson F, van Schaick E, Lundkvist J, Visser SA.

Eur J Clin Pharmacol. 2013 Jun;69(6):1247-60. doi: 10.1007/s00228-012-1459-3. Epub 2013 Jan 4.

Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine

Boada M, Arranz FJ.

Dement Geriatr Cogn Disord. 2013;35(1-2):23-33. doi: 10.1159/000345989. Epub 2013 Jan 9.

[Psychosocial interventions in dementia]

Kurz A.

Nervenarzt. 2013 Jan;84(1):93-103; quiz 104-5. doi: 10.1007/s00115-012-3655-x.

Is there evidence for cognitive intervention in Alzheimer disease? A systematic review of efficacy, feasibility, and cost-effectiveness

Alves J, Magalhães R, Thomas RE, Gonçalves OF, Petrosyan A, Sampaio A.

Alzheimer Dis Assoc Disord. 2013 Jul-Sep;27(3):195-203. doi: 10.1097/WAD.0b013e31827bda55.

Aripiprazole in the treatment of Alzheimer's disease

De Deyn PP, Drenth AF, Kremer BP, Oude Voshaar RC, Van Dam D.

Expert Opin Pharmacother. 2013 Mar;14(4):459-74. doi: 10.1517/14656566.2013.764989. Epub 2013 Jan 28.

Progress of "Current Alzheimer Research" and future direction

Lahiri DK.

Curr Alzheimer Res. 2013 Jan;10(1):1-3. doi: 10.2174/1567205011310010001.

Tackling the elusive challenges relevant to conquering the 100-plus year old problem of Alzheimer's disease

Colom LV, Perry G, Kuljis RO.

Curr Alzheimer Res. 2013 Jan;10(1):108-16. doi: 10.2174/1567205011310010015.

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Förster S, Winter Y, Bach JP, Popp J, Alferink J, Wiltfang J, Buerger K, Otto M, Antuono P, Jacoby M, Richter R, Stevens J, Melamed I, Goldstein J, Haag S, Wietek S, Farlow M, Jessen F.

Lancet Neurol. 2013 Mar;12(3):233-43. doi: 10.1016/S1474-4422(13)70014-0. Epub 2013 Jan 31.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias